LIVIVO - Search results -

Search results

Result 1 - 10 of total 115

Search options

Article ; Online: Anticancer drug therapy for patients with renal dysfunction.

Suyama, Koichi / Miura, Yuji

International journal of clinical oncology

2023 Volume 28, Issue 5, Page(s) 637–643

Abstract: Anticancer drug therapy for cancer is developing rapidly, including molecular-targeted drugs and immune checkpoint inhibitors that are used in clinical settings in addition to conventional cytotoxic drugs. In daily clinical practice, clinicians sometimes ...

Abstract	Anticancer drug therapy for cancer is developing rapidly, including molecular-targeted drugs and immune checkpoint inhibitors that are used in clinical settings in addition to conventional cytotoxic drugs. In daily clinical practice, clinicians sometimes encounter situations in which the effects of these chemotherapeutic agents are considered unacceptable in high-risk patients with liver or renal dysfunction, those undergoing dialysis and older adults. There is no clear evidence regarding anticancer drugs administration to patients with renal dysfunction. However, there are indications for dose setting based on the theory of the renal function responsible for drug excretion and past administration experience. This review outlines anticancer drugs' administration in patients with renal dysfunction.
MeSH term(s)	Humans ; Aged ; Antineoplastic Agents/adverse effects ; Neoplasms/drug therapy ; Renal Dialysis ; Kidney Diseases/drug therapy ; Kidney Diseases/chemically induced
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2023-03-28
Publishing country	Japan
Document type	Journal Article ; Review
ZDB-ID	1400227-9
ISSN	1437-7772 ; 1341-9625
ISSN (online)	1437-7772
ISSN	1341-9625
DOI	10.1007/s10147-023-02315-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4828: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: Significance of Continuous Low-Dose Lenvatinib for the Treating of the Patients with Unresectable Thyroid Carcinoma.

Murakami, Daizo / Nishimoto, Kohei / Takao, Soshi / Miyamaru, Satoru / Kadowaki, Tomoka / Saito, Haruki / Takeda, Hiroki / Ise, Momoko / Suyama, Koichi / Orita, Yorihisa

Acta medica Okayama

2024 Volume 78, Issue 1, Page(s) 63–70

Abstract: The tyrosine kinase inhibitor lenvatinib has been confirmed as an effective treatment option for patients with unresectable thyroid carcinoma. We conducted a retrospective analysis of the significance of the effect of continued lenvatinib treatment for ... ...

Abstract	The tyrosine kinase inhibitor lenvatinib has been confirmed as an effective treatment option for patients with unresectable thyroid carcinoma. We conducted a retrospective analysis of the significance of the effect of continued lenvatinib treatment for the longest duration possible at a reasonable daily dose and with a minimum discontinuation period in 42 patients with unresectable thyroid carcinoma treated with lenvatinib between 2015 and 2020. A Cox proportional hazard model-based analysis revealed that the overall survival of the patients treated with a <8 mg/day mean dose of lenvatinib was significantly better than that of the patients treated with 8-24 mg/day (hazard ratio [HR] 0.38 for 1.14-4.54 mg/day, and HR 0.01 for 4.56-7.97 mg/day) adjusted for various factors (e.g., sex, age, drug interruption period). The cumulative dose of lenvatinib administered tended to be higher in the patients treated with low doses (< 8 mg/day) than in the patients treated with relatively high doses (8-24 mg/day). Considering its adverse events, the continuation of lenvatinib treatment with an adequate daily dose and drug interruption may help prolong the survival of patients with unresectable thyroid carcinoma.
MeSH term(s)	Humans ; Retrospective Studies ; Antineoplastic Agents/therapeutic use ; Thyroid Neoplasms/drug therapy ; Phenylurea Compounds/therapeutic use ; Carcinoma ; Quinolines
Chemical Substances	lenvatinib (EE083865G2) ; Antineoplastic Agents ; Phenylurea Compounds ; Quinolines
Language	English
Publishing date	2024-02-29
Publishing country	Japan
Document type	Journal Article
ZDB-ID	188415-3
ISSN	0386-300X ; 0001-6152
ISSN	0386-300X ; 0001-6152
DOI	10.18926/AMO/66672
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.421: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series.

Yamanaka, Taro / Takemura, Kohji / Hayashida, Michikata / Suyama, Koichi / Urakami, Shinji / Miura, Yuji

Cancer chemotherapy and pharmacology

2023 Volume 92, Issue 3, Page(s) 235–240

Abstract: Purpose: Rhabdomyolysis, which is primarily characterized by serum creatine kinase (CK) elevation, is a potentially fatal disease, and it can occur in a variety of etiologies, including drug-induced. Cabozantinib is one of the standard treatments for ... ...

Abstract	Purpose: Rhabdomyolysis, which is primarily characterized by serum creatine kinase (CK) elevation, is a potentially fatal disease, and it can occur in a variety of etiologies, including drug-induced. Cabozantinib is one of the standard treatments for patients with renal cell carcinoma (RCC). This retrospective case series aimed to investigate the frequency of cabozantinib-induced CK elevation and rhabdomyolysis, and to reveal their detailed clinical features. Methods: To investigate the frequency of cabozantinib-induced serum CK elevation and rhabdomyolysis, we retrospectively reviewed the clinical information and laboratory data of the patients with advanced RCC who received cabozantinib monotherapy at our institution from April 2020 to April 2023. Data were retrieved from the electronic medical records and the RCC database of our institution. Primary endpoint of the current case series was the frequency of CK elevation and rhabdomyolysis. Results: Sixteen patients were retrieved form the database and 13 were included in the case series (excluded by clinical trial enrollment [n = 2] and short-term administration [n = 1]). Eight (61.5%) patients among them experienced serum CK elevation, including five patients who were classified into grade 1. CK elevation occurred a median of 14 days after initiation of cabozantinib. Two patients with grade 2 or 3 of CK elevation developed rhabdomyolysis with muscle weakness and/or acute kidney injury. Conclusions: CK elevation may frequently happen during cabozantinib treatment, and in most cases, it may be asymptomatic and may not be clinically problematic. However, medical providers should be aware that symptomatic CK elevations suggestive of rhabdomyolysis may occasionally occur.
MeSH term(s)	Humans ; Retrospective Studies ; Carcinoma, Renal Cell/drug therapy ; Rhabdomyolysis/chemically induced ; Creatine Kinase ; Kidney Neoplasms/drug therapy
Chemical Substances	cabozantinib (1C39JW444G) ; Creatine Kinase (EC 2.7.3.2)
Language	English
Publishing date	2023-06-28
Publishing country	Germany
Document type	Journal Article
ZDB-ID	6820-2
ISSN	1432-0843 ; 0344-5704 ; 0943-9404
ISSN (online)	1432-0843
ISSN	0344-5704 ; 0943-9404
DOI	10.1007/s00280-023-04557-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1420: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Potential contribution of floral thermogenesis to cold adaptation, distribution pattern, and population structure of thermogenic and non/slightly thermogenic

Sato, Mitsuhiko P / Matsuo, Ayumi / Otsuka, Koichi / Takano, Kohei Takenaka / Maki, Masayuki / Okano, Kunihiro / Suyama, Yoshihisa / Ito-Inaba, Yasuko

Ecology and evolution

2023 Volume 13, Issue 7, Page(s) e10319

Abstract: ... The ... ...

Abstract	The genus
Language	English
Publishing date	2023-07-15
Publishing country	England
Document type	Journal Article
ZDB-ID	2635675-2
ISSN	2045-7758
ISSN	2045-7758
DOI	10.1002/ece3.10319
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Bell's palsy during rechallenge of immune checkpoint inhibitor.

Takemura, Kohji / Yamanaka, Taro / Hayashida, Michikata / Kizawa, Rika / Yamaguchi, Takeshi / Tanabe, Yuko / Sakaguchi, Kazushige / Suyama, Koichi / Urakami, Shinji / Miura, Yuji

IJU case reports

2023 Volume 6, Issue 2, Page(s) 144–146

Abstract: Introduction: The peripheral nervous system is one of the target organs of immune-related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features ...

Abstract	Introduction: The peripheral nervous system is one of the target organs of immune-related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features are not well known. Case presentation: A man with renal cell carcinoma who received rechallenging immune checkpoint inhibitor therapy developed unilateral facial palsy and was diagnosed with Bell's palsy. He did not have any severe immune-related adverse events during his previous immune checkpoint inhibitor treatment. Corticosteroid therapy was immediately initiated, and his facial palsy symptoms promptly improved. Conclusion: Physicians should be aware that Bell's palsy can occur as an immune-related adverse event. Additionally, careful observation is necessary during rechallenge with immune checkpoint inhibitors, even in patients who did not have previous immune-related adverse events.
Language	English
Publishing date	2023-01-16
Publishing country	Australia
Document type	Case Reports
ISSN	2577-171X
ISSN (online)	2577-171X
DOI	10.1002/iju5.12572
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Preoperative frailty as a predictive factor for postoperative complications in patients with pancreatic cancer.

Onji, Makoto / Kakizoe, Shinji / Naito, Koichi / Date, Kenjiro / Nakai, Asuka / Shimizu, Kanami / Suyama, Masatake / Nakamura, So / Kuga, Hirotaka / Nishihara, Kazuyoshi

Nagoya journal of medical science

2023 Volume 85, Issue 3, Page(s) 518–527

Abstract: Frailty is considered one of the most important indicators of a patient's general condition. However, only a few studies have investigated the association between preoperative frailty and postoperative complications in pancreatic cancer. Therefore, this ... ...

Abstract	Frailty is considered one of the most important indicators of a patient's general condition. However, only a few studies have investigated the association between preoperative frailty and postoperative complications in pancreatic cancer. Therefore, this study aimed to examine this association in patients with pancreatic cancer. We retrospectively reviewed 52 consecutive patients who underwent pancreatectomy for pancreatic cancer between July 2019 and March 2021. Patients were classified into two groups according to the presence of postoperative complications. Their characteristics and clinical parameters, including physical function, were analyzed. Patients with postoperative complications had a higher prevalence of frailty (58.8% vs 14.3%,
MeSH term(s)	Humans ; Frailty/diagnosis ; Frailty/epidemiology ; Retrospective Studies ; Risk Factors ; Pancreatic Neoplasms/surgery ; Postoperative Complications/epidemiology ; Postoperative Complications/etiology ; Pancreatic Neoplasms
Language	English
Publishing date	2023-10-05
Publishing country	Japan
Document type	Journal Article
ZDB-ID	193148-9
ISSN	2186-3326 ; 0027-7622
ISSN (online)	2186-3326
ISSN	0027-7622
DOI	10.18999/nagjms.85.3.518
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Granulocyte Colony-stimulating Factor-associated Aortitis on Gallium Scintigraphy.

Ozaki, Haruka / Takemura, Kohji / Kizawa, Rika / Yamaguchi, Takeshi / Komiyama, Chinatsu / Tachi, Masato / Maruno, Hirotaka / Tanabe, Yuko / Suyama, Koichi / Miura, Yuji

Internal medicine (Tokyo, Japan)

2023 Volume 62, Issue 21, Page(s) 3163–3166

Abstract: Aortitis is a rare adverse event associated with granulocyte colony-stimulating factor (G-CSF). Contrast-enhanced computed tomography (CECT) is widely used to diagnose G-CSF-associated aortitis. However, the usefulness of gallium scintigraphy for the ... ...

Abstract	Aortitis is a rare adverse event associated with granulocyte colony-stimulating factor (G-CSF). Contrast-enhanced computed tomography (CECT) is widely used to diagnose G-CSF-associated aortitis. However, the usefulness of gallium scintigraphy for the diagnosis of G-CSF-associated aortitis is unknown. We herein report a set of pre- and post-treatment gallium scintigrams of a patient with G-CSF-associated aortitis. During the diagnosis, gallium scintigraphy revealed hot spots on the arterial walls that appeared inflamed on CECT. Both the CECT and gallium scintigraphy findings disappeared. Gallium scintigraphy can be a supportive diagnostic tool for G-CSF-associated aortitis, especially in patients with an impaired renal function or allergy to iodine contrast.
MeSH term(s)	Humans ; Aortitis/diagnostic imaging ; Aortitis/chemically induced ; Granulocyte Colony-Stimulating Factor/adverse effects ; Radionuclide Imaging ; Tomography, X-Ray Computed ; Gallium
Chemical Substances	Granulocyte Colony-Stimulating Factor (143011-72-7) ; Gallium (CH46OC8YV4)
Language	English
Publishing date	2023-03-22
Publishing country	Japan
Document type	Journal Article
ZDB-ID	32371-8
ISSN	1349-7235 ; 0021-5120 ; 0918-2918
ISSN (online)	1349-7235
ISSN	0021-5120 ; 0918-2918
DOI	10.2169/internalmedicine.1453-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers.

Suyama, Koichi / Iwase, Hirotaka

Cancer control : journal of the Moffitt Cancer Center

2018 Volume 25, Issue 1, Page(s) 1073274818789361

Abstract: Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT) ...

Abstract	Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET). These receptors are important for tumor angiogenesis, and lenvatinib inhibits tumor angiogenesis by inhibiting function of these receptors. Phase I trials of lenvatinib were conducted at the same time in Japan, Europe, and the United States, and tumor shrinkage effects were observed in thyroid cancer, endometrial cancer, melanoma, renal cell carcinoma, sarcoma, and colon cancer. Lenvatinib is a promising drug that has shown therapeutic effects against various solid tumors. Adverse events, such as hypertension, proteinuria, diarrhea, and delayed wound healing, can occur with lenvatinib treatment. Managing these adverse events is also important for the use of lenvatinib. In this mini-review article, we outline the current state, toxicity, and future prospects of lenvatinib toward thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and lung cancer.
MeSH term(s)	Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Clinical Trials, Phase I as Topic ; Diarrhea/chemically induced ; Diarrhea/epidemiology ; Humans ; Hypertension/chemically induced ; Hypertension/epidemiology ; Incidence ; Molecular Targeted Therapy/methods ; Neoplasms/blood supply ; Neoplasms/drug therapy ; Neovascularization, Pathologic/drug therapy ; Phenylurea Compounds/pharmacology ; Phenylurea Compounds/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Proteinuria/chemically induced ; Proteinuria/epidemiology ; Quinolines/pharmacology ; Quinolines/therapeutic use ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors ; Treatment Outcome
Chemical Substances	Antineoplastic Agents ; Phenylurea Compounds ; Protein Kinase Inhibitors ; Quinolines ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1) ; lenvatinib (EE083865G2)
Language	English
Publishing date	2018-07-22
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1328503-8
ISSN	1526-2359 ; 1073-2748
ISSN (online)	1526-2359
ISSN	1073-2748
DOI	10.1177/1073274818789361
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4467: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Survey of Advance Care Planning Practices in Elderly COVID-19 Patients: A Multicenter Questionnaire Survey.

Morio, Ryosuke / Takazono, Takahiro / Kubo, Ryotaro / Fukushima, Koki / Suyama, Naofumi / Izumikawa, Takuya / Izumikawa, Koichi / Yanagihara, Katsunori / Mukae, Hiroshi

Cureus

2023 Volume 15, Issue 5, Page(s) e39663

Abstract: Objective Advance care planning (ACP) is a process in which the patient and family discuss end-of-life care in advance with healthcare providers in case decisional ability declines. Due to the rapid deterioration of symptoms and isolation for treatment, ... ...

Abstract	Objective Advance care planning (ACP) is a process in which the patient and family discuss end-of-life care in advance with healthcare providers in case decisional ability declines. Due to the rapid deterioration of symptoms and isolation for treatment, it is not easy for COVID-19 patients to discuss their end-of-life care with families and medical staff. We conducted a questionnaire survey to assess the current situation of ACP practices in hospitalized COVID-19 patients. Materials and methods Multicenter questionnaire surveys of hospitalized COVID-19 patients aged ≥60 years between January 2021 and August 2022 were conducted in two hospitals. The questionnaires assessed whether patients had discussed end-of-life medical treatment with their families and family physicians at the time of admission and their preferences for end-of-life medical treatments. Results A total of 109 patients aged 60-99 years (median 75.0 years) were enrolled. Only eight patients (7.3%) had practiced ACP at the time of admission. Age was a significant factor related to ACP practices (p=0.035). Although there was no significant difference between the ACP and non-ACP practiced groups for each end-of-life care, all eight patients in the ACP-practiced group were able to make decisions for all the end-of-life medical treatment, while 40 patients (33.0%) in the non-ACP-practiced group did not, showing a significant difference (p=0.026). Conclusion In hospitalized COVID-19 patients, the rate of ACP practice was as low as 7.3%. Awareness of ACP practice is necessary, especially for elderly patients with underlying diseases.
Language	English
Publishing date	2023-05-29
Publishing country	United States
Document type	Journal Article
ZDB-ID	2747273-5
ISSN	2168-8184
ISSN	2168-8184
DOI	10.7759/cureus.39663
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Simultaneous Tumor Shrinkage and Bronchial Perforation Induced by Nivolumab plus Cabozantinib Combination Therapy in a Patient with Collecting Duct Carcinoma.

Okumura, Hiroki / Murase, Kyoko / Oka, Suguru / Kizawa, Rika / Yamaguchi, Takeshi / Tanabe, Yuko / Suyama, Koichi / Sakaguchi, Kazushige / Urakami, Shinji / Miura, Yuji

Chemotherapy

2023 Volume 69, Issue 1, Page(s) 45–48

Abstract: Vascular endothelial growth factor receptor tyrosine kinase inhibitors are known to cause perforation as one of their severe side effects, and postoperative and postradiation therapy are known risk factors. However, there are few studies on perforation ... ...

Abstract	Vascular endothelial growth factor receptor tyrosine kinase inhibitors are known to cause perforation as one of their severe side effects, and postoperative and postradiation therapy are known risk factors. However, there are few studies on perforation following tumor shrinkage. A 78-year-old woman with postoperative recurring left collecting duct carcinoma of the right hilar lymph nodes and mediastinum underwent eight courses of nivolumab plus cabozantinib, resulting in tumor shrinkage. Three days after the last administration, she developed fever and cough and was hospitalized for right lobar pneumonia. The patient received long-term antibiotics for bronchial fistula with the destruction of the bronchial wall and secondary lung abscess. When using nivolumab plus cabozantinib combination therapy for a tumor with bronchial invasion, physicians should be aware of bronchial perforation as the tumor shrinks.
MeSH term(s)	Female ; Humans ; Aged ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/pathology ; Nivolumab/therapeutic use ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/pathology ; Vascular Endothelial Growth Factor A/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Anilides ; Pyridines
Chemical Substances	Nivolumab (31YO63LBSN) ; cabozantinib (1C39JW444G) ; Vascular Endothelial Growth Factor A ; Anilides ; Pyridines
Language	English
Publishing date	2023-10-11
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	6708-8
ISSN	1421-9794 ; 0009-3157
ISSN (online)	1421-9794
ISSN	0009-3157
DOI	10.1159/000534470
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uf I Zs.174: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito